Zimmer Biomet Holdings (ZBH) Cost of Revenue (2009 - 2026)

Zimmer Biomet Holdings has reported Cost of Revenue for 18 years, with the latest figure at $635.5 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 7.31% year-over-year to $635.5 million in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 13.06% increase from a year earlier, with the FY2025 full-year figure at $2.5 billion, up 13.81% from the prior year.
• Cost of Revenue was $635.5 million for Q2 2026 at Zimmer Biomet Holdings, up from $576.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $792.4 million in Q4 2025, with the low at $488.2 million in Q3 2022.
• Average Cost of Revenue over 5 years is $555.5 million, with a median of $538.7 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue fell 3.02% in 2022, then soared 35.06% in 2025.
• Over 5 years, Cost of Revenue stood at $520.3 million in 2022, then gained by 3.56% to $538.8 million in 2023, then grew by 8.89% to $586.7 million in 2024, then jumped by 35.06% to $792.4 million in 2025, then retreated by 19.8% to $635.5 million in 2026.
• The last three Cost of Revenue figures came in at $635.5 million (Q2 2026), $576.2 million (Q1 2026), and $792.4 million (Q4 2025), per Business Quant data.